| EBV-specific T cell activator | T cell source | Prophylaxis for | EBV-specific pathology | References |
|---|---|---|---|---|
| LCL | Transplant donor derived | Post-HSCT PTLD | 0/101 developed PTLD | Rooney et al., 1995, 1998; Heslop et al., 1996, 2010 |
| 5/6 exhibited a decrease in EBV DNA | Gustafsson et al., 2000 | |||
| 1/4 decrease in EBV DNA | Comoli et al., 2007 | |||
| Allogeneic | Post-HSCT PTLD | 0/1 showed evidence of viral activation (EBV, CMV, ADV) | Naik et al., 2016 | |
| DCs + LCLs transduced with ADV | Transplant donor derived | Post-HSCT PTLD | 0/1 showed evidence of viral activation (EBV, CMV, ADV) | |
| DCs + LCLs transduced with ADV + CMV pp65 | Transplant donor derived | Post-HSCT PTLD | 0/2 showed evidence of viral activation (EBV, CMV, ADV) | |
| Allogeneic | Post-HSCT PTLD | 0/3 showed evidence of viral activation (EBV, CMV, ADV) | ||
| Viral Ags from EBV, CMV, ADV | Transplant donor derived | Post-HSCT PTLD | 0/2 showed evidence of viral activation (EBV, CMV, ADV) |
Abbreviations used: ADV, adenovirus.